Esomeprazole sodium

CAS No. 161796-78-7

Esomeprazole sodium( S)-Omeprazole sodium )

Catalog No. M12368 CAS No. 161796-78-7

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 37 In Stock
10MG 55 In Stock
25MG 87 In Stock
50MG 113 In Stock
100MG 146 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Esomeprazole sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.
  • Description
    A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-(?)-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved(In Vitro):Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.(In Vivo):Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.
  • In Vitro
    Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. Cell Viability AssayCell Line:MDA-MB-468 cellsConcentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
  • In Vivo
    Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis. Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury Dosage:30 mg/kg, 300 mg/kg Administration:Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
  • Synonyms
    S)-Omeprazole sodium
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Proton Pump
  • Recptor
    H+/K+-ATPase
  • Research Area
    Other Indications
  • Indication
    Ulcer

Chemical Information

  • CAS Number
    161796-78-7
  • Formula Weight
    367.3979
  • Molecular Formula
    C17H18N3NaO3S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in H2O
  • SMILES
    CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+]
  • Chemical Name
    1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CS-526

    CS-526 (AKU 517;R 105266) is a potent, competitive, and reversible acid pump antagonist (potassium-competitive acid blocker) that inhibits H+,K+-ATPase activity with IC50 of 61 nM.

  • Tegoprazan

    A novel potent, highly selective, competitive and orally active inhibitor of gastric H+/K+-ATPase with IC50 of ranging 0.29-0.52 uM porcine, canine and human H+/K+-ATPases in vitro.

  • AZD-0865

    A potent, selective acid pump antagonist (potassium-competitive acid blocker or P-CAB) that reversiblely inhibits gastric H+/K+-ATPase with pIC50 of 6.5.